Literature DB >> 24823954

Left ventricular reverse remodeling, device-related adverse events, and long-term outcome after cardiac resynchronization therapy in the elderly.

Ulas Höke1, Hein Putter1, Enno T Van Der Velde1, Martin J Schalij1, Victoria Delgado1, Jeroen J Bax1, Nina Ajmone Marsan2.   

Abstract

BACKGROUND: Limited data are available on efficacy, safety, and long-term prognosis after cardiac resynchronization therapy (CRT) in elderly patients. We aimed at evaluating the effect of CRT, device-related adverse events, and long-term outcome after CRT among elderly patients. METHODS AND
RESULTS: A total of 798 CRT recipients (208 elderly: age, ≥75 years; 590 nonelderly: age, <75 years) underwent clinical and echocardiographic evaluation at baseline and 6-month follow-up. Elderly patients had similar improvements in clinical symptoms, left ventricular function, and left ventricular reverse remodeling as their counterparts. Similar rates of device-related in-hospital (within 24 hours; P=0.552), early (within 30 days; P=0.984), and long-term adverse events (entire follow-up; hazard ratio, 0.90; P=0.620) were observed between groups. During long-term follow-up (median, 38.6 months; interquartile range, 22.5-61.8 months), all-cause mortality rate was significantly higher among the elderly patients. However, the differences in cumulative event rates started after 4 years of follow-up (P=0.013), and the cause of death was mainly noncardiac (29% in the elderly versus 19% in nonelderly; P<0.001). Diabetes mellitus (hazard ratio, 2.322; P=0.019), impaired renal function (hazard ratio, 0.975; P=0.006), and reduced 6-minute walk distance (hazard ratio, 0.996; P<0.019) were independently associated with all-cause mortality in elderly patients.
CONCLUSIONS: CRT efficacy and device-related adverse events in elderly patients were comparable with that of nonelderly patients. However, after 4 years of follow-up, elderly patients showed worse survival and the cause of death was mainly noncardiac. Diabetes mellitus, impaired renal function, and reduced 6-minute walk distance were independently associated with all-cause mortality of elderly patients.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  aged; cardiac resynchronization therapy; heart failure; prognosis

Mesh:

Year:  2014        PMID: 24823954     DOI: 10.1161/CIRCOUTCOMES.113.000821

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  11 in total

Review 1.  Implantable Cardioverter-Defibrillator Use in Older Adults: Proceedings of a Hartford Change AGEnts Symposium.

Authors:  Daniel B Kramer; Daniel D Matlock; Alfred E Buxton; Nathan E Goldstein; Carol Goodwin; Ariel R Green; James N Kirkpatrick; Christopher Knoepke; Rachel Lampert; Paul S Mueller; Matthew R Reynolds; John A Spertus; Lynne W Stevenson; Susan L Mitchell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-06-02

2.  Device therapy: CRT effective in elderly patients with heart failure.

Authors:  Tim Geach
Journal:  Nat Rev Cardiol       Date:  2014-06-03       Impact factor: 32.419

Review 3.  Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management.

Authors:  Pow-Li Chia; David Foo
Journal:  Singapore Med J       Date:  2016-07       Impact factor: 1.858

Review 4.  Device Management in Heart Failure.

Authors:  Brett G Angel; Heath Saltzman; Luke S Kusmirek
Journal:  Curr Cardiol Rep       Date:  2017-09-25       Impact factor: 2.931

Review 5.  Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection?

Authors:  Martin H Ruwald
Journal:  J Atr Fibrillation       Date:  2015-06-30

6.  Cardiac resynchronization in the elderly is beneficial, but could we implant our devices in old patients safer?

Authors:  Evgeny N Mikhaylov; Dmitry S Lebedev
Journal:  J Geriatr Cardiol       Date:  2016-03       Impact factor: 3.327

7.  Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy.

Authors:  Zhonglin Han; Zheng Chen; Rongfang Lan; Wencheng Di; Xiaohong Li; Hongsong Yu; Wenqing Ji; Xinlin Zhang; Biao Xu; Wei Xu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

Review 8.  Impact of baseline renal function on all-cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and meta-analysis.

Authors:  G Bazoukis; K P Letsas; P Korantzopoulos; C Thomopoulos; K Vlachos; S Georgopoulos; N Karamichalakis; A Saplaouras; M Efremidis; A Sideris
Journal:  J Arrhythm       Date:  2017-05-01

9.  Predictors of clinical outcomes after cardiac resynchronization therapy in patients ≥75 years of age: a retrospective cohort study.

Authors:  Laure Champ-Rigot; Anne-Laure Cornille; Pierre Ollitrault; Arnaud Pellissier; Mathieu Chequel; Damien Legallois; Paul Milliez
Journal:  BMC Geriatr       Date:  2019-11-21       Impact factor: 3.921

10.  Clinical outcomes and mortality in old and very old patients undergoing cardiac resynchronization therapy.

Authors:  Luiz Eduardo Montenegro Camanho; Eduardo Benchimol Saad; Charles Slater; Luiz Antonio Oliveira Inacio Junior; Gustavo Vignoli; Lucas Carvalho Dias; Pedro Pimenta de Mello Spineti; Ricardo Mourilhe-Rocha
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.